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Abstract
Purpose: Postoperative radiation therapy (RT) is commonly used for World Health Organization grade II-III intracranial ependymoma.
Clinicians generally aim to begin RT ≤5 weeks after surgery, but postoperative recovery and need for second look surgery can delay the
initiation of adjuvant therapy. On ACNS 0831, patients were required to enroll ≤8 weeks after initial surgery and begin adjuvant therapy
within 3 weeks after enrollment. The purpose of this study was to determine the optimal timing of RT after surgery.
Methods and Materials: The National Cancer Database was queried for patients (aged 1-39 years) with localized World Health
Organization grade II-III intracranial ependymoma treated with surgery and postoperative RT. Overall survival (OS) curves were
plotted based on RT timing (≤5 weeks, 5-8 weeks, and >8 weeks after surgery) and were compared by log-rank test. Factors
associated with OS were identified by multivariate analysis. After 2009, complete data were available on whether patients underwent
gross total resection or subtotal resection. Planned subset analysis was performed to examine the effect of RT timing on OS in patients
with known extent of resection.
Results: In the final analytical data set of 1043 patients, no difference in 3-year OS was observed in patients who initiated RT ≤5
weeks, 5 to 8 weeks, and >8 weeks after surgery (89.8% vs 89.1% vs 88.4%; P = .796). On multivariate analysis, grade III tumors
(hazard ratio, 2.752; 95% confidence interval, 1.969-3.846, P < .001) and subtotal resection (hazard ratio, 2.253; 95% confidence
interval, 1.405-3.611, P < .001) were significantly associated with reduced OS. Timing of RT, total RT dose, age, and other factors
were not significant. These findings were affirmed in the subset of patients treated between 2010 and 2016, when extent of resection
was routinely recorded.
Conclusions: Delayed postoperative RT was not associated with inferior survival in patients with intracranial ependymoma. Delayed
RT initiation may be acceptable in patients who require longer postoperative recovery or referral to an appropriate RT center, but
should be minimized whenever practical.
© 2021 The Author(s). Published by Elsevier Inc. on behalf of American Society for Radiation Oncology. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Introduction
Ependymoma is the second-most common malignant
intracranial tumor in pediatric patients, with approxi-
mately 1372 new cases diagnosed per year in the United
States.1 Pediatric ependymoma are almost exclusively
located within the brain, with two-thirds residing in the
posterior fossa. Maximal safe resection is the primary
curative treatment in all patients. Adjuvant radiation ther-
apy (RT) is generally recommended in patients with
World Health Organization (WHO) grade II-III ependy-
moma after maximal safe resection.2 The role of chemo-
therapy is not well characterized3; however, in very
young patients, adjuvant chemotherapy may be used to
delay RT due to concerns about late adverse effects.4-6
The optimal timing between surgical resection and
adjuvant RT has been examined in medulloblastoma7,8
but not in ependymoma. Many physicians strive to begin
within 5 weeks of surgery, similar to many malignant
brain tumors. Selected patients, however, may experience
unavoidable delays to enable adequate postoperative
recovery or to facilitate referral to a high volume pediat-
ric center. All patients in Children’s Oncology Group
ACNS 0121 and ACNS 0831 (NCT01096368) were
required to enroll within 8 weeks of initial surgery and
initiation of adjuvant therapy within 3 weeks from enroll-
ment. Currently, there are limited data demonstrating the
effect of delayed RT on overall survival (OS).
The aim of our study was to analyze the association
between the time interval from surgical resection to adju-
vant RT on OS in patients with ependymoma using the
National Cancer Database (NCDB). We hypothesized that
delayed adjuvant RT may be associated with decreased OS.
Methods and Materials
Study design and population
We analyzed deidentified patient data obtained from
the NCDB, a large hospital-based registry that captures
approximately 70% of all cancer incidence in the United
States from more than 1500 hospitals accredited by the
Commission on Cancer. The NCDB is a joint project of
the Commission on Cancer and the American College of
Surgeons. The data used in the study were derived from a
deidentified NCDB file. The American College of Sur-
geons and the Commission on Cancer have not verified
and are not responsible for the analytical or statistical
methodology employed or the conclusions drawn from
these data by the investigators. After evaluation and
approval of the research design by the clinical trials
office, institutional review board approval was not
required for this study.
Patients with ependymoma between the ages of 1 and
39 years were identified in the NCDB data set using
primary site and histology codes.1 The analytical cohort
was generated to include patients who received diagnoses
of ependymoma between 2004 and 2016, which yielded
2433 subjects. Patients were excluded if they had WHO
grade I or IV tumors, history of prior malignancy, meta-
static disease, received radiation doses <50 or ≥61.5 Gy,
or had incomplete data for vital status or date of last con-
tact. Patients were also excluded if they received only 1
treatment modality with either surgery or RT or received
RT before surgery. The final analytical cohort included
1043 patients. The selection criteria for the final data set
are illustrated in Figure 1.
Complete information on extent of surgical resection
was not included in the NCDB until 2010. A planned sub-
group analysis was performed for all patients who had
complete information on extent of surgical resection,
classified as either gross total resection (GTR) or subtotal
resection (STR)/biopsy. This yielded 565 patients for this
subgroup analysis, representing all patients diagnosed
and treated from 2010 to 2016.
The primary exposure of our study was time between
initial surgery and the start of adjuvant RT, divided into 3
strata (<5 weeks, 5-8 weeks, >8 weeks). The primary
outcome was OS. Additional covariates included age (1-
20, 21-39), race, sex, WHO grade (II, III), tumor location
(supratentorial, infratentorial), extent of surgical resec-
tion (GTR, STR), Charlson Deyo comorbidity score (0,
1, 2, or 3), insurance status (private, Medicaid/govern-
ment, uninsured), distance from hospital (≤50 miles, >50
miles), year of diagnosis (2004-2006, 2007-2009, 2010-
2012, 2013-2015), household income (stratified by quar-
tile), and RT dose (≤54 Gy, >54 Gy).
Statistical analysis
Statistical analysis was performed using SPSS version
26.0 (SPSS Inc, Chicago, IL). Differences between cate-
gorical variables were compared using the x2 test. Sur-
vival curves were plotted using the Kaplan-Meier
product limit method and were compared using the log-
rank test. Multivariate proportional hazards analysis
(MVA) with backward stepwise regression was used to
identify factors associated with OS. Two-sided P values
< .05 were considered statistically significant. The pro-
portional hazards assumption was tested for a nonzero
slope in the generalized linear model using scaled
Schoenfeld residuals. Multiple imputation methods were
used to address limitations due to missing data.
Results
Patient demographics and tumor characteristics are
presented in Table 1. Median age was 9 years (interquar-
tile range, 3-22). Younger patients (age <21 years) and
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those with grade III tumors were more likely to begin
postoperative RT earlier after initial surgery than older
patients and those with grade II tumors. All other com-
parisons showed no significant and/or no clear discern-
able difference between the groups. Median follow-up
was 4.77 years for surviving patients. At the close-out
date, 17.3% of patients had died.
In this cohort, no significant OS difference was
observed between patients who received adjuvant RT <5
weeks, 5 to 8 weeks, or >8 weeks after surgical resection,
with 3-year OS rates of 89.8%, 89.1%, and 88.4%
(P = .796), respectively. The Kaplan-Meier plots are
illustrated in Figure 2. Similarly, no significant difference
in OS was observed in the subgroup of patients treated
between 2010 and 2016 with known extent of surgical
resection (P = .802). The Kaplan-Meier curves for this
subgroup are shown in Figure 3.
On MVA, we observed no significant association
between the timing of postoperative RT and OS (Table 2).
In the complete data set, WHO grade III tumors were sig-
nificantly associated with increased hazard of death (haz-
ard ratio [HR], 2.752; 95% confidence interval [CI],
1.969-3.846, P < .001) compared with WHO grade II
tumors. STR was also associated with an increased risk
of death (HR, 2.253; 95% CI, 1.405-3.611, P <.001).
Age, sex, race, distance from hospital, household income,
insurance, tumor location, RT dose, and Charlson Deyo
score demonstrated no association with OS.
In the subgroup of patients with known extent of
resection, MVA illustrated similar findings relative to the
primary analytical cohort. WHO grade III tumors (HR,
4.296; 95% CI, 2.334-7.906, P < .001) and STR (HR,
2.267; 95% CI, 1.381-3.721, P = .001) remained signifi-
cant on MVA. Postoperative RT timing and other addi-
tional variables were not associated with OS.
Discussion
We evaluated the effect of the time interval between
surgery and postoperative RT on survival in patients with
intracranial ependymoma using a large hospital-based
registry. Our study demonstrated no significant difference
in OS between patients who received early versus
delayed RT in the NCDB.
To our knowledge, no large database studies to date
have evaluated the effect of postoperative RT timing on
outcomes in ependymoma. Patteson and colleagues9
recently reported no detriment in OS or local control if
RT started within 9 weeks in a single institution study of





History of prior malignancy [n=66]
WHO Grade I and IV tumors [n=121]
Metastac disease [n=49]




Radiaon dose <50 Gy or >61.5 Gy [n=965]
1075
Exclusion:
Paents who received one modality treatment, RT 
before surgery, or addional RT [n=32]
1043
Subgroup Analysis:
Missing data for GTR/STR, which were paents treated 
between 2006-2009 [n=478]
565
Figure 1 Inclusion and exclusion criteria used to select the primary analytical data set and the planned subgroup analysis.
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145 patients with intracranial ependymoma. The authors
reported a trend toward inferior local control in WHO
grade II patients after GTR/ (near total resection) with
RT initiation later than 9 weeks after surgery but did not
observe this in grade III patients.9 No such discrepancy
based on WHO grade was observed in this analysis.
The effect of RT timing on OS was previously evalu-
ated in medulloblastoma using the NCDB. Chin and
Table 1 Patient demographics and tumor characteristics
Patient characteristics Total Time to RT <5 weeks Time to RT 5-8 weeks Time to RT >8 weeks P value
No. % No. % No. % No. %
Total age (years) 1043 100 334 100 363 100 346 100
< .001
1-20 752 72.1 266 79.6 274 75.5 212 61.3
21-39 291 27.9 68 20.4 89 24.5 134 38.7
Race .673
White 828 79.4 263 78.7 296 81.5 269 77.8
Nonwhite 153 14.7 53 15.9 46 12.7 54 15.6
Unknown 62 5.9 18 5.4 21 5.8 23 6.7
Sex .076
Male 576 55.2 191 57.2 211 58.1 174 50.3
Female 467 44.8 143 42.8 152 41.9 172 49.7
Charlson Deyo score .570
0 953 91.4 307 91.9 333 91.7 313 90.5
1 64 6.1 19 5.7 22 6.1 23 6.7
2 15 1.4 3 0.9 7 1.9 5 1.5
3 11 1.1 5 1.5 1 0.3 5 1.5
Insurance .107
Private 630 60.4 197 59.0 236 65.0 197 56.9
Medicaid/gov. 341 32.7 112 33.5 108 29.8 121 35.0
Uninsured 54 5.2 22 6.6 14 3.9 18 5.2




≤50 miles 790 75.7 252 75.5 279 76.9 259 74.9
>50 miles 253 24.3 82 24.6 84 23.1 87 25.1
Median income .107
1st quartile (Lowest) 248 23.8 72 21.6 94 25.9 82 23.7
2nd quartile 198 19.0 68 20.4 58 16.0 72 20.8
3rd quartile 270 25.9 78 23.4 99 27.3 93 26.9
4th quartile (Highest) 324 31.1 113 33.8 112 30.9 99 28.6
Unknown 3 0.3 3 0.9 0 0.0 0 0.0
Year of diagnosis .612
2004-2006 242 23.2 78 23.4 92 25.3 73 20.8
2007-2009 236 22.6 79 23.7 84 23.1 73 21.1
2010-2012 273 26.2 90 27.0 90 24.8 93 26.9
2013-2015 292 28.0 87 26.1 97 26.7 108 31.2
WHO grade .004*
Grade II 576 55.2 166 49.7 195 53.7 215 62.1
Grade III 467 44.8 168 50.3 168 46.3 131 37.9
Tumor location .320
Infratentorial 355 34.0 112 33.5 118 32.5 125 36.1
Supratentorial 392 37.6 126 37.7 150 41.3 116 33.5
Unknown 296 28.4 96 28.7 95 26.2 105 30.4
Surgical resection .005*
GTR 378 36.2 130 38.9 130 35.8 118 34.1
STR 188 18.0 47 14.1 57 15.7 84 24.3
Unknown 477 45.7 157 47.0 176 48.5 144 41.6
RT dose (Gy) < .001*
≤54 367 35.2 102 30.5 113 31.1 152 43.9
>54 676 64.8 232 69.5 250 68.9 194 56.1
Abbreviations: GTR = gross total resection; RT = radiation therapy; STR = subtotal resection; WHO = World Health Organization.
* Significant values with P < 0.05.
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colleagues8 reported no clear effect on survival from
delaying RT up to 90 days after surgery. Of note, the
authors found that initiation of RT within 3 weeks of sur-
gery was associated with inferior survival, although they
noted that this finding may have been explained by an
imbalance in adverse factors, such as presence of meta-
static disease, in that group.8 Owing to concern regarding
neurocognitive deficits after craniospinal irradiation,
Figure 3 Overall survival curves as a function of postoperative radiation therapy timing in patients treated between 2010 and 2016
(n = 565), when extent of surgical resection was known in all patients.
Figure 2 Overall survival curves as a function of postoperative radiation therapy timing in the primary analytical data set (n = 1043
patients). No significant difference in overall survival was observed as a function of radiation therapy timing.
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Table 2 Multivariate analysis for overall survival
Variable Entire data set (n = 1043) Subgroup (n = 565)
HR (95% CI) P value HR (95% CI) P value
Time to adjuvant RT (weeks)
<5 Reference Reference
5-8 0.902 (0.623-1.305) .583 0.819 (0.445-1.507) .521
>8 1.075 (0.739-1.563) .706 0.973 (0.545-1.736) .926
WHO tumor grade
Grade II Reference Reference
Grade III 2.752 (1.969-3.846) < .001* 4.296 (2.334-7.906) < .001*
Tumor location
Infratentorial Reference Reference
Supratentorial 0.748 (0.509-1.098) .138 0.767 (0.415-1.420) .399
Unknown 0.937 (0.639-1.376) .741 0.873 (0.450-1.694) .688
Surgical resection
GTR Reference Reference
STR 2.253 (1.405-3.611) < .001* 2.267 (1.381-3.721) .001*
Unknown 1.429 (0.958-2.131) .0810
RT dose (Gy)
≤54 Reference Reference
>54 1.040 (0.738-1.465) .822 1.069 (0.610-1.875) .815
Age
1-20 Reference Reference
21-39 0.880 (0.601-1.288) .510 1.109 (0.632-1.946) .718
Race
White Reference Reference
Nonwhite 0.423 (0.246-0.727) .002 0.465 (0.213-1.016) .055
Unknown 0.762 (0.371-1.565) .458 0.592 (0.139-2.516) .477
Sex
Male Reference Reference
Female 0.813 (0.596-1.108) .190 0.879 (0.536-1.443) .611
Charlson Deyo score
0 Reference Reference
1 1.157 (0.665-2.013) .606 1.090 (0.424-2.801) .859
2 0.915 (0.223-3.759) .902 0.772 (0.101-5.886) .803
3 1.242 (0.296-5.220) .767 1.387 (0.177-10.892) .756
Insurance status
Private Reference Reference
Medicaid/Medicare/govt. 1.064 (0.757-1.497) .720 1.308 (0.761-2.248) .331
Uninsured 1.402 (0.715-2.747) .325 1.759 (0.684-4.523) .241
Unknown 2.408 (1.025-5.655) .044 7.371 (1.935-28.075) .003
Residential distance to hospital (miles)
≤50 Reference Reference
>50 0.759 (0.517-1.114) .159 0.550 (0.282-1.073) .080
Median income
1st quartile (lowest) Reference Reference
2nd quartile 1.200 (0.763-1.885) .430 1.324 (0.664-2.640) .425
3rd quartile 0.842 (0.550-1.289) .430 0.788 (0.371-1.677) .537
4th quartile (highest) 0.703 (0.452-1.094) .118 0.880 (0.447-1.734) .713
Unknown 3.332 (0.435-25.496) .246
Year of Diagnosis
2004-2006 Reference
2007-2009 1.123 (0.752-1.677) .570
2010-2012 0.004 (0.000-0.039) < .001* Reference
2013-2015 0.002 (0.000-0.025) < .001* 0.586 (0.331-1.040) .068
Abbreviations: CI = confidence interval; GTR = gross total resection; HR = hazard ratio; RT = radiation therapy; STR = subtotal resection;
WHO = World Health Organization.
* Significant values with P < 0.05.
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younger patients with medulloblastoma less commonly
receive RT than older patients. Kann and colleagues7
reported that deferral of RT in patients with medulloblas-
toma between 3 to 8 years of age was associated with sig-
nificantly worse OS in the NCDB, affirming the
importance of RT on survival in this population.
Adjuvant RT is generally recommended after maximal
safe resection of grade II-III intracranial ependymoma.
The role of RT has also been questioned in selected popu-
lations, including children with grade II supratentorial
tumors after GTR and adults.10,11 Mature results from
ACNS 0831 will provide further information on the for-
mer group. The role of adjuvant RT is arguably more
controversial in adults. Prabhu and colleagues11 reported
no OS benefit with adjuvant RT in adults (≥22 years old)
who received RT. In that cohort, 80% of patients had
grade II tumors and two-thirds were supratentorial com-
pared with 55.2% grade II and 37.6% supratentorial in
this study. We hypothesize that differences in the inci-
dence of different molecular subtypes of ependymoma
between pediatric and adult patients may explain this
observed variation in tumor characteristics and poten-
tially lead to the observed differences in survival between
manuscripts. In 2016, Ramaswamy and colleagues12
reported clinically significant OS differences for patients
with posterior fossa A and B (PFA and PFB) infratento-
rial tumors, and a clear benefit from adjuvant RT in PFA
tumors. The authors concluded that selected patients with
PFB tumors may safely be observed after GTR, but vali-
dation in a prospective trial is needed to definitively
address this hypothesis.
For many malignant pediatric and adult brain tumors,
postoperative RT regularly begins within 5 weeks of ini-
tial surgery to reduce the risk that any microscopic or
gross residual disease may repopulate after surgery.13
Delaying RT initiation, however, may provide several
competing benefits. For example, it may also enable time
for patients to undergo second look surgery to achieve
GTR or permit patients to complete inpatient physical
therapy when necessary. Finally, it may provide adequate
time to develop a high quality treatment plan or be
referred to a high volume pediatric RT center.
In this analysis, both STR and WHO grade III tumors
were significantly associated with inferior OS, consistent
with prior studies.14-16 Male gender was previously
reported as an adverse risk factor, but was not significant
in this analysis.15 Metastatic disease is another known
adverse prognostic factor, but such patients were
excluded from this analytical set. Of note, no dose
response was observed for patients receiving <54 Gy in
either the primary cohort or the subgroup analysis with
known extent of surgical resection. This finding is con-
cordant with 2 recent reports9,17 but not with a recent
NCDB analysis. Ager and colleagues18 reported a dose
response for OS in children aged 2 to 18 treated with >54
Gy with no benefit from dose escalation observed in
adults and children <2 years old. After adjusting for sig-
nificant prognostic factors in the MVA, delayed RT tim-
ing was not associated with an elevated HR for death in
this analysis.
Several limitations in our study must be acknowl-
edged. First, selection and information biases are often-
times inseparable from retrospective analyses and must
be considered when applying our results to clinical prac-
tice. Extent of resection was reported in only 54.3% of
the primary analytical cohort, which cannot be easily
overcome. Missing information can affect results in reg-
istry-based series, and data coding errors certainly exist
within large databases. A planned subset analysis demon-
strated no clear difference in the survival estimates
observed in only the patients with known GTR/STR sta-
tus. The completeness of the remaining available data
and this step helped to counter the possibility that the
observed effect was due to selection bias. Of note, the
role of adjuvant chemotherapy is still uncertain in pediat-
ric ependymoma,3 but it may be elucidated by coopera-
tive group trials.
In the NCDB, outcome measures were limited to OS;
data regarding local and distant failure and cancer-spe-
cific survival cannot be extracted. Although this is a
known limitation of NCDB analyses, the predominant
cause of mortality in children diagnosed with malignant
brain tumors is either related to the tumor or its treatment.
This is particularly true during early follow-up, with
competing risks of death rising in later years19 as the inci-
dence of significant comorbidities related to curative
therapy increases.20,21 Although the NCDB provides ade-
quate power to address hypotheses regarding RT timing,
duration of follow-up remains one limitation. Ependy-
moma can recur >5 years after diagnosis and treatment,
and long-term follow-up is important for this5 and other
pediatric brain tumors. We acknowledge that follow-up
was only 4.77 years in this study, and that delayed RT
may lead to an increased risk of local failure and a result-
ing effect on survival with longer follow-up than in this
data set. In addition, due to its granularity, large data-
bases like the NCDB do not provide a clear explanation
for why particular treatments were selected, such as why
patients received delayed RT. For example, selected
patients who received delayed RT may have done so after
a second look surgery; this could potentially explain the
observed lack of difference in OS in this analysis as a
function of RT timing. We further recognize that obser-
vational studies cannot replace randomized data as the
standard for outcomes research, although registry data
can address important clinical questions not adequately
evaluated in randomized trials.
Molecular subtype information for ependymoma is not
included in the NCDB. This classification system is con-
temporary22 and evolving23,24 and has only recently been
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incorporated into routine testing. Of note, ACNS 0121
demonstrated no clear difference in event-free survival
between PFA and B infratentorial tumors or based on
RELA fusion status but did identify significantly inferior
event-free survival with 1q gain.4,15 In the future, molec-
ular data should be regularly recorded in cooperative
group trials and large registries for ependymoma and
other brain tumors to better understand the effect of
molecular subtype on outcomes.
In summary, our NCDB analysis demonstrated no
clear survival effect with delayed RT in pediatric and
young adult patients with localized intracranial ependy-
moma. Selected patients, including those with metastatic
disease, may benefit from early RT administration. Given
the clear importance of GTR on survival, we advise com-
plete surgical resection whenever feasible, even if second
look surgery is required, leading to a delay in adjuvant
RT. This approach is consistent with ACNS 0121 and
ACNS0831.15 Routine delays in postoperative RT should
be avoided, but these data suggest that it may be consid-
ered in selected patients who may benefit from second
look surgery, require additional time for adequate heal-
ing, or to facilitate referral to a high volume RT center.
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